| Ticker Symbol: |
MRK - USA Markets |
| Stock Last Traded Price: |
$54.87 |
| Stock Last Traded At: |
1/17/2008 3:14pm |
| Change: |
-3.48 |
| Opened At: |
$57.84 |
| Day Range: |
$58.40 - $54.47 |
| Volume: |
22840204
|
| Page Last Updated: |
1/17/2008 - 3:14pm |
- Sector Roundup: Generics, Loan Insurers (AP)
- Wall St. sinks on economic worries, Merrill (Reuters)
- Stocks slump on recession fears (at CNNMoney.com)
- Business Events Scheduled for Friday (AP)
- Sector Snap: Generic Drug Makers (AP)
- Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough (PR Newswire)
- Midday Leaders & Laggards: DJIA (AP)
- Virus may cause rare but deadly skin cancer (at Reuters)
- Election Year Politics May Scare Off Pharma Investors (CNBC)
- Factory activity, Merrill drag down market (Reuters)
- Vytorin-palooza: Schering's Science, Patients' Worries & LDL (at The Wall Street Journal Online)
- Pharma Investors: Will Political Talk Scare Them Off? (at CNBC)
- Novartis profit drops 45%; plans $9 billion buyback (at MarketWatch)
- Novartis says focusing on Galvus in Europe (at Reuters)
- Novartis Diabetes Drug May Never Be Sold in U.S. (at The Wall Street Journal Online)
- Study Missteps Threaten Turnaround at Schering (at The Wall Street Journal Online)
- Cutting Through the Confusion Over Vytorin (at The Wall Street Journal Online)
- Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia (PR Newswire)
- Congress Investigates Vytorin Ads (at The Wall Street Journal Online)
- [$$] EU Raids Drug Firms in Antitrust Probe (at The Wall Street Journal Online)
Sector Roundup: Generics, Loan Insurers (AP)
Merck & Co.'s impending patent loss on blockbuster osteoporosis drug Fosamax will significantly benefit the generic drug industry in 2008, a JP Morgan analyst predicted Thursday....
Wall St. sinks on economic worries, Merrill (Reuters)...
Stocks slump on recession fears (at CNNMoney.com)...
Business Events Scheduled for Friday (AP)
Major business events and economic events scheduled for Friday: NEW ORLEANS -- Hearing at which Merck & Co. is expected to update the number of plaintiffs participating in its landmark Vioxx settlement....
Sector Snap: Generic Drug Makers (AP)
Merck & Co.'s impending patent loss on blockbuster osteoporosis drug Fosamax will significantly benefit the generic drug industry in 2008, a JP Morgan analyst predicted Thursday....
Hagens Berman Sobol Shapiro Files Suit Against Merck and Schering-Plough (PR Newswire)
Hagens Berman Sobol Shapiro filed a proposed class-action lawsuit against Merck and Schering-Plough , manufacturers of Zetia and Vytorin, alleging Merck and Schering-Plough violated state consumer protection laws arising from the sale and marketing of Zetia and Vytorin....
Midday Leaders & Laggards: DJIA (AP)
Shares of insurer American International Group Inc. absorbed the biggest midday decline on the Dow Jones industrial average Thursday, as the blue chip index appeared to be headed for its third straight loss....
Virus may cause rare but deadly skin cancer (at Reuters)...
Election Year Politics May Scare Off Pharma Investors (CNBC)
If or when you watch one of the presidential| debates count how many times the candidates say, "the drug companies." Of course, it depends on which party's debate you might be watching, but since I started paying attention to the race in recent weeks, I've taken notice how much those three words seem to be apart of boilerplate answers and statements......
Factory activity, Merrill drag down market (Reuters)...
Vytorin-palooza: Schering's Science, Patients' Worries & LDL (at The Wall Street Journal Online)...
Pharma Investors: Will Political Talk Scare Them Off? (at CNBC)...
Novartis profit drops 45%; plans $9 billion buyback (at MarketWatch)
Swiss drugmaker Novartis on Thursday reported a 45% drop in its fourth-quarter profit, after taking a $444 million charge to revamp a business affected by copycat competition and the failure to roll out new drugs on time....
Novartis says focusing on Galvus in Europe (at Reuters)...
Novartis Diabetes Drug May Never Be Sold in U.S. (at The Wall Street Journal Online)...
Study Missteps Threaten Turnaround at Schering (at The Wall Street Journal Online)...
Cutting Through the Confusion Over Vytorin (at The Wall Street Journal Online)...
Hagens Berman Sobol Shapiro Announces Investigation Into Marketing of Vytorin and Zetia (PR Newswire)
Hagens Berman Sobol Shapiro has begun an investigation concerning actions by Merck and Schering-Plough , manufacturers of Zetia and Vytorin. The investigation is looking into charges of whether Merck and Schering-Plough violated state consumer protection laws arising from the sale and marketing of Zetia and Vytorin....
Congress Investigates Vytorin Ads (at The Wall Street Journal Online)...
[$$] EU Raids Drug Firms in Antitrust Probe (at The Wall Street Journal Online)... |
